» Articles » PMID: 8164038

Relationship of Patient Age to Pathologic Features of the Tumor and Prognosis for Patients with Stage I or II Breast Cancer

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1994 May 1
PMID 8164038
Citations 149
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This analysis was performed to clarify the relationship of young age at diagnosis to the pathologic features of the tumor and prognosis in patients with early-stage breast cancer.

Patients And Methods: We retrospectively analyzed data from 1,398 patients with American Joint Committee on Cancer Staging stage I or II breast cancer treated by breast-conserving therapy between 1968 and 1985. One hundred seven patients were younger than 35 years at the time of diagnosis. The median follow-up duration for the 1,032 survivors was 99 months.

Results: Patients younger than 35 years had a significantly higher overall recurrence rate (P = .002), as well as a greater risk for developing distant metastases (P = .03), when compared with older patients. The cancers in younger patients more commonly showed factors associated with a worse prognosis (including grade 3 histology, lymphatic vessel invasion [LVI], necrosis, and estrogen receptor [ER] negativity) as compared with older patients. In a proportional hazards model that included clinical and treatment-related variables, as well as these pathologic features, age younger than 35 years remained a significant predictor for time to recurrence (relative risk [RR], 1.70), time to distant failure (RR, 1.60), and overall mortality (RR, 1.50).

Conclusion: Breast cancer patients younger than 35 years have a worse prognosis than older patients. This difference is only partially explained by a higher frequency of adverse pathologic factors seen in younger patients.

Citing Articles

Age and Late Recurrence in Young Patients With ER-Positive, ERBB2-Negative Breast Cancer.

Shin D, Lee J, Kang E, Noh D, Cheun J, Lee J JAMA Netw Open. 2024; 7(11):e2442663.

PMID: 39509133 PMC: 11544499. DOI: 10.1001/jamanetworkopen.2024.42663.


Patient-Related Awareness of Impact of Cancer-Directed Therapy on Fertility in Young Women Diagnosed of Breast Cancer.

Nair N, Ali B, Siddique S, Maheshwari A, Bajpai J, Parmar V South Asian J Cancer. 2024; 13(3):215-219.

PMID: 39410988 PMC: 11473132. DOI: 10.1055/s-0043-1771385.


Ferroptosis-related gene signature and clinical prognostic factors as prognostic marker for colon adenocarcinoma.

Zeng Q, Han L, Hong Q, Wang G, Xue X, Fang Y Heliyon. 2024; 10(14):e33794.

PMID: 39100449 PMC: 11295570. DOI: 10.1016/j.heliyon.2024.e33794.


Survival pattern in male breast cancer: distinct from female breast cancer.

Gwark S, Kim J, Chung I, Kim H, Ko B, Lee J Front Oncol. 2024; 14:1392592.

PMID: 39007102 PMC: 11239393. DOI: 10.3389/fonc.2024.1392592.


Genetic Testing of Breast Cancer Patients with Very Early-Onset Breast Cancer (≤30 Years) Yields a High Rate of Germline Pathogenic Variants, Mainly in the BRCA1, TP53, and BRCA2 Genes.

Apostolou P, Dellatola V, Papathanasiou A, Kalfakakou D, Fountzilas E, Tryfonopoulos D Cancers (Basel). 2024; 16(13).

PMID: 39001430 PMC: 11240773. DOI: 10.3390/cancers16132368.